AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 151 min read$IPSC

Carr Douglas sold $3K of IPSC

Carr Douglas (SVP Finance & Operations) sold 1,658 shares of Century Therapeutics, Inc. (IPSC) at $1.93 on 2026-09-14.

Original reporting
SEC EDGAR · Carr Douglas
Published Sep 15, 2026, 10:25 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 11:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$IPSC
Neutral
high confidence
Mentioned
$IPSC
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IPSCNeutralLow
01

Why it matters

The sale is routine and unlikely to move the stock.

02

Market read

Low relevance; minor insider sale with no material impact.

03

What to watch

Potential future dilution or secondary offerings could change significance.

Relevance 3/10Novelty 3/10Timing: Filed Sep 15, 2026 (same‑day filing)

Background

Form 4 filings disclose insider transactions; traders monitor them for signals.

Company-level read

Ticker impact

$IPSCNeutralHigh confidence
Context

SVP Finance & Operations Carr Douglas sold 1,658 shares of Century Therapeutics at $1.93 each, total $3,199.94.

Expected impact

No material price movement expected.

Evidence & confidence

The transaction size is small relative to total float and holdings; such sales are routine and unlikely to affect price.

Market effects

Sector

None; the sale does not signal broader trends in biotech.

Regional

No regional effect.

Global

Limited to investors tracking insider activity.

Counterpoint

What could challenge this read

Even small insider sales can hint at upcoming negative news, but no evidence here.

Key entities

  • Company
    Century Therapeutics, Inc.

    Biotech firm listed on Nasdaq under IPSC.

  • Insider
    Carr Douglas

    SVP Finance & Operations, reported insider sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

IPSC insider trading history →

Related articles

OCT 2
$IPSCMedAI 8/10

Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026

Century Therapeutics, Inc. (IPSC) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026 Data demonstrated scalable production, in vivo function and immune evasion, and updated progress toward clinical dosing of CNTY-813, Centur

SEC EDGAR 8-K2 min
OCT 2
$IPSCMedAI 8/10

Century Therapeutics presents diabetes therapy data at EASD

Century Therapeutics (NASDAQ:IPSC) presented data on CNTY-813, a diabetes therapy, at the EASD meeting. The therapy showed long-term glycemic control in mouse models and successful engraftment in rats. The company plans to submit an IND application in Q4 2026, with clinical data expected in H2 2027, according to the press release.

investing.com2 min
OCT 2
$IPSCMed

Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026

Century Therapeutics (NASDAQ: IPSC) presented nonclinical data for CNTY-813, its iPSC-derived islet replacement therapy for type 1 diabetes, at EASD 2026. Data showed glycemic control in diabetic mice, scalable production, and immune evasion. The company expects to submit an IND application in Q4 2026 and anticipates initial clinical data in 2H 2027.

globenewswire.com3 min
AUG 18
$IPSCHighAI 8/10

Century Targets FDA Filing for Diabetes Cell Therapy

Century Therapeutics (NASDAQ: IPSC) aims to file for FDA approval of its diabetes cell therapy, CNTY-813, in Q4 2026, with initial human data expected in 2027. The company reported $197.2M in cash as of Q2 2026, sufficient to fund operations into Q1 2029. Preclinical results showed promising glucose control and immune evasion, but clinical outcomes are not guaranteed. Century also advances CNTY-308, a CAR-iT cell therapy, with IND-enabling work on track for 2026. Q2 R&D expenses decreased 27% to

mychesco.com3 min